Tests mezigdomide with elranatamab in people with relapsed multiple myeloma
Tests mezigdomide plus elranatamab, to find a safe dose, in adults with relapsed myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Key facts
- Where
- Calgary, Halifax, Toronto, and Vancouver, CanadaSee the 4 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose multiple myeloma came back or stopped responding after earlier treatment. It tests mezigdomide together with elranatamab.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma that came back or did not respond to treatment (relapsed and refractory). The myeloma must be measurable by local laboratory tests.
- Earlier treatment
- Phase 1: 2 to 4 earlier lines of anti-myeloma treatment. Phase 2: 1 to 3 earlier lines. No earlier mezigdomide, T cell engager or BCMA-targeting treatment, except BCMA-targeted CAR-T cell therapy given more than 6 months before the study starts.
Main reasons for not taking part
- Earlier treatment with mezigdomide
- Earlier treatment with a T cell engager
- Earlier BCMA-targeting treatment, except BCMA-targeted CAR-T cell therapy given more than 6 months before the study starts
- ECOG performance status above 1
- Not following the contraception requirements
Read by machine on 12 November 2026.
Where in Canada
- Arthur J.E. Child Comprehensive Cancer CentreCalgary, CanadaTaking people
- QEII Health Sciences Centre, Victoria General SiteHalifax, CanadaTaking people
- Princess Margaret Cancer CentreToronto, CanadaTaking people
- Vancouver, British ColumbiaHospital not named in the registryNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Celgene
- Trial code
- NCT06988488EU 2025-522090-11-00
- Record updated
- 2 September 2026
- Original description
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).Read full original descriptionShow less
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Inclusion: Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3 prior lines of anti-myeloma therapy (Phase 2); Measurable MM by local laboratory; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1; Adherence to contraception requirements.
Exclusion: Prior treatment with mezigdomide; Prior treatment with T cell engaging or T cell engager (TCE); Prior treatment with B cell-maturation antigen (BCMA)-targeting therapy, with the exception of participants who have received autologous BCMA-targeted CART-cell therapy> 6 months from the start of study therapy; Other protocol-defined Inclusion/Exclusion criteria apply.